Provided by Tiger Trade Technology Pte. Ltd.

Beam Therapeutics, Inc.

25.52
-1.9200-7.00%
Post-market: 25.800.2800+1.10%19:49 EST
Volume:2.09M
Turnover:54.16M
Market Cap:2.59B
PE:-31.51
High:27.12
Open:26.71
Low:25.44
Close:27.44
52wk High:36.44
52wk Low:13.53
Shares:101.47M
Float Shares:89.94M
Volume Ratio:0.80
T/O Rate:2.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8100
EPS(LYR):-0.8100
ROE:-8.11%
ROA:-18.55%
PB:2.09
PE(LYR):-31.51

Loading ...

Beam Therapeutics higher after reaching FDA alignment on BEAM-302

TIPRANKS
·
Jan 13

Beam Therapeutics rises 23.4%

TIPRANKS
·
Jan 12

BRIEF-Beam Therapeutics Says It Sets Strategic Priorities For Its Genetic Disease & Hematology Franchises

Reuters
·
Jan 12

Beam Therapeutics Extends Cash Runway Into 2029 and Advances Clinical Programs

Reuters
·
Jan 12

Beam Therapeutics Projects Cash Runway Into 2029

Reuters
·
Jan 12

Beam Therapeutics Inc - Risto-Cel Bla Submission Expected by Year-End 2026

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Inc - to Announce New Liver-Targeted Program in H1 2026

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Inc - FDA Alignment on Accelerated Approval Pathway for Beam-302

THOMSON REUTERS
·
Jan 12

Beam Therapeutics Sets Strategic Priorities for Its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends Its Operating Runway Through Commercial Transition

THOMSON REUTERS
·
Jan 12

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Benzinga_recent_news
·
Jan 01

Beam Therapeutics (BEAM): Reassessing Valuation After New BEACON risto-cel Data in Sickle Cell Disease

Simply Wall St.
·
Dec 19, 2025

Beam Therapeutics Nets $255 Million From Orbital Therapeutics Sale

Reuters
·
Dec 12, 2025

Beam Therapeutics Reports Durable Efficacy and Safety for Risto-cel in Sickle Cell Disease Trial

Reuters
·
Dec 06, 2025

Beam Therapeutics Reports Updated Data From Beacon Phase 1/2 Trial of Ristoglogene Autogetemcel (Risto-Cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (Scd) at American Society of Hematology (Ash) Annual Meeting

THOMSON REUTERS
·
Dec 06, 2025

Beam Therapeutics (BEAM) Is Up 6.8% After Analyst Optimism Around Sickle Cell Base-Editing Progress - What's Changed

Simply Wall St.
·
Dec 05, 2025

Does Beam Therapeutics' $1.1B Cash Position and Clinical Progress Reinforce the BEAM Investment Case?

Simply Wall St.
·
Nov 19, 2025

Cathie Wood Bets Big on This Peter Thiel-Backed Coinbase Rival as Bitcoin Crashes Below $91,000

Benzinga
·
Nov 18, 2025

Beam Therapeutics’ BEAM-101: Advancements in Sickle Cell Disease Therapy and Manufacturing Efficiency Drive Buy Rating

TIPRANKS
·
Nov 14, 2025

RBC Capital Sticks to Their Hold Rating for Beam Therapeutics (BEAM)

TIPRANKS
·
Nov 06, 2025

Beam Therapeutics (BEAM) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Nov 05, 2025